anti-CD30 CAR T-cell therapy (Cartherics/Monash University)

N/A

Report date: 2025/01/26 18:41:02

Base Information

Drug Nameanti-CD30 CAR T-cell therapy (Cartherics/Monash University)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionTumor necrosis factor receptor superfamily member 8 modulators
TargetsTumor necrosis factor receptor superfamily member 8
Therapy Area/IndicationsLymphoma, T-Cell, Cutaneous
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia and New Zealand
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMonash University
China Registration ClassN/A

Develop Information

Active CompaniesCartherics Pty LtdMonash University
Inactive CompaniesN/A
Active IndicationsLymphoma, T-Cell, Cutaneous
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A